Gwo Xi Stem Cell Applied Technology Co. , Ltd (6704.TWO) stock: key figures, P/E, revenue and dividend

Health Care · Taiwan · ISIN TW0006704000

Price
20.35 TWD
Market cap
1.95 bn TWD
P/E (2025)
–
P/S (2025)
10.44
Dividend yield
0.00 %
Net margin
-43.05 %
Return on equity (ROE)
-13.87 %
Return on assets (ROA)
-8.23 %

Gwo Xi Stem Cell Applied Technology Co. , Ltd financials

Fiscal year20242025
Revenue170.03 m TWD187.02 m TWD
Gross profit116.64 m TWD131.97 m TWD
Operating income-75.93 m TWD-73.67 m TWD
EBIT-71.88 m TWD-70.69 m TWD
Net income-83.32 m TWD-80.52 m TWD
Diluted EPS – continuing operations-0.87 TWD-0.84 TWD

Full history since 2019, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Gwo Xi Stem Cell Applied Technology Co. , Ltd

Gwo Xi Stem Cell Applied Technology Co. , Ltd develops stem cell technology for patients with unmet medical needs. Its products under development include GXHPC1, an autologous adipose-derived stem cell therapy in phase II clinical trials for use in the treatment of liver cirrhosis; and GXNPC1, an autologous adipose-derived stem cell therapy in phase II clinical trials for use in the treatment of chronic stroke. The company is also developing GXCPC1, an allogeneic adipose-derived stem cells therapy in phase I/II clinical trials for use in the treatment of osteoarthritis; and GXIPC1, an allogeneic adipose-derived stem cells therapy in phase I clinical trials for use in the treatment of diabetes. The company was founded in 2011 and is based in Zhubei, Taiwan.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.